Credit score: Unsplash/CC0 Public Area
A multicenter collaboration of Danish researchers studies that once-weekly semaglutide for 30 weeks lowered blood sugar ranges and physique weight and improved bodily high quality of life in antipsychotic-treated adults with schizophrenia and prediabetes.
Cardiometabolic sickness cuts life expectancy in schizophrenia, with life-style dangers and boundaries to bodily care including to the burden. Second-generation antipsychotics can speed up weight achieve and impair glucose tolerance.
Earlier trials of GLP-1 receptor agonists in psychiatric populations examined shorter programs or completely different brokers and left a necessity for choices that tackle glycemia and weight whereas preserving psychiatric stability.
Within the examine, “Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial,” printed in JAMA Psychiatry, researchers carried out a placebo-controlled, double-blinded randomized medical trial to check whether or not semaglutide improves glycemic management, weight, and high quality of life on this inhabitants.
Enrollment included 154 adults aged 18–60 years receiving second-generation antipsychotics throughout two Danish areas, with 141 finishing 30 weeks. A randomization schedule was supplied by the drug producer, Novo Nordisk, together with semaglutide and a placebo.
Intervention used once-weekly subcutaneous semaglutide or placebo for 30 weeks with an eight-week titration to 1.0 mg or highest tolerated dose.
Visits and assessments happened primarily in individuals’ houses. The first end result was change in blood sugar ranges (HbA1c). Secondary outcomes included physique weight, fasting glucose, lipid measures, and schizophrenia signs primarily based on Constructive and Detrimental Syndrome Scale–6 (PANSS-6), and SF-36v2 bodily and psychological part scores.
Outcomes confirmed an HbA1c discount of 0.46% of complete hemoglobin versus placebo at week 30, with a major impact seen at week 15 and was maintained by way of the ultimate on-treatment evaluation at week 30.
Physique weight fell by 9.21 kg versus placebo at week 30. An HbA1c under 5.7% occurred in 81% on semaglutide versus 19% on placebo. HDL rose by 10.81 mg/dL and triglycerides decreased by 29.20 mg/dL.
An inconsistent significance within the triglyceride lower introduces a crimson flag that must be defined by the examine authors.
The examine studies the info as a lower of -29.20 mg/dL (95% CI, -55.75 to 2.65; P = .03), which can’t be right as a CI that crosses 0 mustn’t have a P worth under .05. It’s possible an indication error (-2.65 vs. the printed +2.65), although it seems in a number of places within the examine together with a number of reversals of CI higher and decrease sure orders.
Bodily high quality of life improved by 3.75 factors. Psychological high quality of life and PANSS-6 scores confirmed no vital between-group variations. Gastrointestinal signs appeared extra usually with semaglutide early in remedy and improved over time. Critical adversarial results didn’t differ between teams.
Authors conclude that semaglutide at 1.0 mg weekly for 30 weeks was secure on this cohort, improved glycemia and weight, and enhanced bodily well-being with out psychiatric deterioration.
Findings recommend a candidate remedy for SGA-treated sufferers with schizophrenia, prediabetes, and weight problems, with authors noting that the potential for weight reduction and prevention of kind 2 diabetes could justify remedy value.
Written for you by our creator Justin Jackson, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this text is the results of cautious human work. We depend on readers such as you to maintain impartial science journalism alive.
If this reporting issues to you,
please think about a donation (particularly month-to-month).
You will get an ad-free account as a thank-you.
Extra data:
Ashok A. Ganeshalingam et al, Semaglutide Therapy of Antipsychotic-Handled Sufferers With Schizophrenia, Prediabetes, and Weight problems, JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.2332
© 2025 Science X Community
Quotation:
Antipsychotic-treated sufferers with schizophrenia see advantages from semaglutide, examine claims (2025, September 17)
retrieved 17 September 2025
from https://medicalxpress.com/information/2025-09-antipsychotic-patients-schizophrenia-benefits-semaglutide.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
